Gene Therapy in Hemophilia: An Introduction to AAV Vector Gene Transfer

Current hurdles in AAV-based gene therapy for hemophiliaПодробнее

Gene Therapy in HemophiliaПодробнее

Introduction to gene therapy for hemophiliaПодробнее

Multiyear Factor VIII Expression after Adeno‐associated Virus Gene Transfer for Hemophilia AПодробнее

AAV Integration Summary and ImplicationsПодробнее

Recent Advances in Gene Therapy for Hemophilia Presented at NHF 2021Подробнее

Valoctocogene Roxaparvovec AAV Gene Transfer for Severe Hemophilia: Results From Phase 3 TrialПодробнее

David Lillicrap, MD, discusses AAV gene therapy in a canine hemophilia modelПодробнее

Synthetic AAV vectors for gene therapy of hemophilia in childrenПодробнее

AAV Gene Transfer for HemophiliaПодробнее

Lentivirus Vectors for Gene Therapy for HemophiliaПодробнее

Long-term Vector Genome Outcomes and Immunogenicity of AAV FVIII Gene Transfer in Hemophilia AПодробнее

Preexisting Antibodies to AAV and Consequences for Hemophilia Gene TherapyПодробнее

Gene Therapy for Hemophilia: AAV Vector Gene Therapy Application to HemophiliaПодробнее

Gene Therapy for Treatment of Hemophilia: AAV Vector Gene Therapy Application to HemophiliaПодробнее

Gene Therapy for Treatment of Hemophilia: An Introduction to AAV Gene TransferПодробнее

Gene Therapy for Treatment of Hemophilia: An Introduction to AAV Vector Gene TransferПодробнее

AAV Vector Manufacturing and AnalyticsПодробнее

Technology Risk Assessment of Present and Future AAV VectorsПодробнее